Related references
Note: Only part of the references are listed.The impact of infliximab induction therapy on mucosal healing and clinical remission in Polish pediatric patients with moderate-to-severe Crohn's disease
Jaroslaw Kierkus et al.
EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY (2012)
Risk of Infection and Prevention in Pediatric Patients With IBD: ESPGHAN IBD Porto Group Commentary
Gigi Veereman-Wauters et al.
JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION (2012)
Severe infusion reactions to infliximab: aetiology, immunogenicity and risk factors in patients with inflammatory bowel disease
C. Steenholdt et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2011)
Mucosal Gene Expression of Cell Adhesion Molecules, Chemokines, and Chemokine Receptors in Patients With Inflammatory Bowel Disease Before and After Infliximab Treatment
Ingrid Arijs et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2011)
Regulatory macrophages: Setting the Threshold for Therapy
Bryan D. Fleming et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2011)
Apoptosis of regulatory T lymphocytes is increased in chronic inflammatory bowel disease and reversed by anti-TNFα treatment
Claudia Veltkamp et al.
GUT (2011)
Cancer in Crohn's Disease Patients Treated with Infliximab: A Long-term Multicenter Matched Pair Study
Livia Biancone et al.
INFLAMMATORY BOWEL DISEASES (2011)
Infliximab and adalimumab-induced psoriasis in Crohn's disease: A paradoxical side effect
Marisa Iborra et al.
JOURNAL OF CROHNS & COLITIS (2011)
Genetics and pathogenesis of inflammatory bowel disease
Bernard Khor et al.
NATURE (2011)
Infliximab Induces Clonal Expansion of γδ-T Cells in Crohn's Disease: A Predictor of Lymphoma Risk?
Jens Kelsen et al.
PLOS ONE (2011)
The tissue inhibitors of metalloproteinases (TIMPs): An ancient family with structural and functional diversity
Keith Brew et al.
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH (2010)
Interleukin-15 and Its Soluble Receptor Mediate the Response to Infliximab in Patients With Crohn's Disease
Gregory Bouchaud et al.
GASTROENTEROLOGY (2010)
Genome Wide Association (GWA) Predictors of Anti-TNFα Therapeutic Responsiveness in Pediatric Inflammatory Bowel Disease
Marla C. Dubinsky et al.
INFLAMMATORY BOWEL DISEASES (2010)
Severe neutropenia following infliximab treatment in a child with ulcerative colitis
Mary Sherlock et al.
INFLAMMATORY BOWEL DISEASES (2010)
Genome-wide meta-analysis increases to 71 the number of confirmed Crohn's disease susceptibility loci
Andre Franke et al.
NATURE GENETICS (2010)
Clinical implications of mucosal healing for the management of IBD
Guillaume Pineton de Chambrun et al.
NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY (2010)
Castleman's disease arising from the gallbladder neck causing difficulty in the differential diagnosis
Kiminori Takano et al.
CLINICAL JOURNAL OF GASTROENTEROLOGY (2010)
Infliximab and other immunomodulating drugs in patients with inflammatory bowel disease and the risk of serious bacterial infections
S. Schneeweiss et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2009)
Mitogen activated protein kinases: a role in inflammatory bowel disease?
O. J. Broom et al.
CLINICAL AND EXPERIMENTAL IMMUNOLOGY (2009)
Modulation of inflammatory response via α2-adrenoceptor blockade in acute murine colitis
A. Bai et al.
CLINICAL AND EXPERIMENTAL IMMUNOLOGY (2009)
Therapeutic Options to Modulate Barrier Defects in Inflammatory Bowel Disease
Nina A. Hering et al.
DIGESTIVE DISEASES (2009)
VEGF-A Links Angiogenesis and Inflammation in Inflammatory Bowel Disease Pathogenesis
Franco Scaldaferri et al.
GASTROENTEROLOGY (2009)
Dietary Histidine Ameliorates Murine Colitis by Inhibition of Proinflammatory Cytokine Production From Macrophages
Ayatoshi Andou et al.
GASTROENTEROLOGY (2009)
Biological Therapies for Inflammatory Bowel Diseases
Paul Rutgeerts et al.
GASTROENTEROLOGY (2009)
Colectomy Rate Comparison After Treatment of Ulcerative Colitis With Placebo or Infliximab
William J. Sandborn et al.
GASTROENTEROLOGY (2009)
Modulation of the Th1/Th2 Balance by Infliximab Improves Hyperthyroidism Associated with a Flare-up of Ulcerative Colitis
Kayoko Matsumura et al.
INFLAMMATORY BOWEL DISEASES (2009)
Infliximab therapy decreases the levels of TNF- and IFN- mRNA in colonic mucosa of ulcerative colitis
Trine Olsen et al.
SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY (2009)
Emerging treatments for complex perianal fistula in Crohn's disease
Carlos Taxonera et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2009)
Review: Predicting response to anti-TNF agents for the treatment of Crohn's disease
Corey A. Siegel et al.
Therapeutic Advances in Gastroenterology (2009)
Increased Efficacy of Delayed-Release Mesalamine 4.8g/D (800mg Tablet) in Patients Previously Diagnosed with Ulcerative Colitis (UC)
William J. Sandborn et al.
GASTROENTEROLOGY (2009)
The role of granulocyte macrophage-colony-stimulating factor in acute intestinal inflammation
Yinghua Xu et al.
CELL RESEARCH (2008)
Mechanisms of action of infliximab in inflammatory bowel disease: an anti-inflammatory multitasker
S. Danese
DIGESTIVE AND LIVER DISEASE (2008)
Current Directions in IBD Therapy: What Goals Are Feasible With Biological Modifiers?
William J. Sandborn
GASTROENTEROLOGY (2008)
IL23 differentially regulates the Th1/Th17 balance in ulcerative colitis and Crohn's disease
T. Kobayashi et al.
GUT (2008)
Anti tumour necrosis-α therapy increases the number of FOXP3+ regulatory T cells in children affected by Crohn's disease
Ida Ricciardelli et al.
IMMUNOLOGY (2008)
Dilation of colonic strictures by intralesional injection of infliximab in patients with Crohn's colitis
Arun Swaminath et al.
INFLAMMATORY BOWEL DISEASES (2008)
Unique CD14+ intestinal macrophages contribute to the pathogenesis of Crohn disease via IL-23/IFN-γ axis
Nobuhiko Kamada et al.
JOURNAL OF CLINICAL INVESTIGATION (2008)
NF-κB in inflammatory bowel disease
I. Atreya et al.
JOURNAL OF INTERNAL MEDICINE (2008)
NLR proteins: integral members of innate immunity and mediators of inflammatory diseases
Jeanette M. Wilmanski et al.
JOURNAL OF LEUKOCYTE BIOLOGY (2008)
Tumor necrosis factor-alpha antagonism improves endothelial dysfunction in patients with Crohn's disease
F. Schinzari et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2008)
Biologics for the treatment of juvenile idiopathic arthritis: a systematic review and critical analysis of the evidence
Gerald Gartlehner et al.
CLINICAL RHEUMATOLOGY (2008)
Unravelling the pathogenesis of inflammatory bowel disease
R. J. Xavier et al.
NATURE (2007)
Functional modulation of crohn's disease myofibroblasts by anti-tumor necrosis factor antibodies
Antonio Di Sabatino et al.
GASTROENTEROLOGY (2007)
The efficacy and tolerability of newer biologics in rheumatoid arthritis: best current evidence
M. Asif A. Siddiqui
CURRENT OPINION IN RHEUMATOLOGY (2007)
Early changes in rectal nitric oxide and mucosal inflammatory mediators in Crohn's colitis in response to infliximab treatment
T. Ljung et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2007)
Effect of the anti-tumor necrosis factor-α antibody infliximab on the ex vivo mucosal matrix metalloproteinase-proteolytic phenotype in inflammatory bowel disease
Martin J. Meijer et al.
INFLAMMATORY BOWEL DISEASES (2007)
Role of matrix metalloproteinases in intestinal inflammation
Carlos Medina et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2006)
Angiogenesis as a novel component of inflammatory bowel disease pathogenesis
Silvio Danese et al.
GASTROENTEROLOGY (2006)
Probiotics and inflammatory bowel diseases
A-P Bai et al.
POSTGRADUATE MEDICAL JOURNAL (2006)
Both IL-12p70 and IL-23 are synthesized during active Crohn's disease and are down-regulated by treatment with anti-IL-12 p40 monoclonal antibody
IJ Fuss et al.
INFLAMMATORY BOWEL DISEASES (2006)
Infliximab for induction and maintenance therapy for ulcerative colitis
P Rutgeerts et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Abnormally differentiated subsets of intestinal macrophage play a key role in Th1-dominant chronic colitis through excess production of IL-12 and IL-23 in response to bacteria
N Kamada et al.
JOURNAL OF IMMUNOLOGY (2005)
Polymorphisms in apoptosis genes predict response to infliximab therapy in luminal and fistulizing Crohn's disease
T Hlavaty et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2005)
Tumor necrosis factor family members and inflammatory bowel disease
J Wang et al.
IMMUNOLOGICAL REVIEWS (2005)
Increased levels of NF-kappa B inhibitors (I kappa B alpha and I kappa B gamma) in the intestinal mucosa of Crohn's disease patients during infliximab treatment
L Guidi et al.
INTERNATIONAL JOURNAL OF IMMUNOPATHOLOGY AND PHARMACOLOGY (2005)
Infliximab maintenance therapy for fistulizing Crohn's disease
BE Sands et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Downregulation of epithelial apoptosis and barrier repair in active Crohn's disease by tumour necrosis factor α antibody treatment
S Zeissig et al.
GUT (2004)
Inhibition of p38 MAP kinase- and RICK/NF-κB-signaling suppresses inflammatory bowel disease
E Hollenbach et al.
FASEB JOURNAL (2004)
Smoking and immunomodulators do not influence the response or duration of response to infliximab in Crohn's disease
DS Fefferman et al.
INFLAMMATORY BOWEL DISEASES (2004)
Increased production of granulocyte-macrophage colony-stimulating factor in Crohn's disease - a possible target for infliximab treatment
J Agnholt et al.
EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY (2004)
Anti-interleukin-12 antibody for active Crohn's disease
PJ Mannon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
New cytokine therapeutics for inflammatory bowel disease
PCF Stokkers et al.
CYTOKINE (2004)
Defective mucosal T cell death is sustainably reverted by infliximab in a caspase dependent pathway in Crohn's disease
A Di Sabatino et al.
GUT (2004)
Optimizing anti-TNF treatment in inflammatory bowel disease
P Rutgeerts et al.
GASTROENTEROLOGY (2004)
Human antichimeric antibody in children and young adults with inflammatory bowel disease receiving infliximab
E Miele et al.
JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION (2004)
An analysis of factors influencing short-term and sustained response to infliximab treatment for Crohn's disease
IDR Arnott et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2003)
Infliximab but not etanercept induces apoptosis in lamina propria T-lymphocytes from patients with Crohn's disease
JMH Van Den Brande et al.
GASTROENTEROLOGY (2003)
Cytokine and anti-cytokine therapies for inflammatory bowel disease
H Ogata et al.
CURRENT PHARMACEUTICAL DESIGN (2003)
Down-regulation of intestinal lymphocyte activation and Th1 cytokine production by antibiotic therapy in a murine model of Crohn's disease
G Bamias et al.
JOURNAL OF IMMUNOLOGY (2002)
Predictors of response to infliximab in patients with Crohn's disease
MA Parsi et al.
GASTROENTEROLOGY (2002)
p38 mitogen-activated protein kinase is activated and linked to TNF-α signaling in inflammatory bowel disease
GH Waetzig et al.
JOURNAL OF IMMUNOLOGY (2002)
Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial
SB Hanauer et al.
LANCET (2002)
Infliximab downregulates interferon-γ production in activated gut T-lymphocytes from patients with Crohn's disease
J Agnholt et al.
CYTOKINE (2001)
Decreased Bax expression by mucosal T cells favours resistance to apoptosis in Crohn's disease
J Itoh et al.
GUT (2001)
Infliximab induces potent anti-inflammatory and local immunomodulatory activity but no systemic immune suppression in patients with Crohn's disease
F Cornillie et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2001)
Mechanisms in failure of infliximab for Crohn's disease
S Nikolaus et al.
LANCET (2000)
The key role of macrophages in the immunopathogenesis of inflammatory bowel disease
YR Mahida
INFLAMMATORY BOWEL DISEASES (2000)
Share Paper
